利奈唑胺杂质22 | 264601-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 利奈唑胺杂质22
• 英文名称: (R)-3-(4'-N-morpholinophenyl)-5-(hydroxymethyl)-oxazolidin-2-one
• 英文别名: (R)-5-(hydroxymethyl)-3-(4-morpholinophenyl)oxazolidin-2-one；(5R)-5-(hydroxymethyl)-3-(4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
• CAS: 264601-17-4
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: XBIDNDZEMBYVFR-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  利奈唑胺杂质22 在 甲基磺酰氯 、 三乙胺 、 potassium phtalimide 、 一水合肼 作用下， 以 二氯甲烷 、 乙腈 、 甲醇 为溶剂， 反应 2.75h， 生成 (S)-5-氨基甲基-3-(4-吗啉基苯基)-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939):  An Oral, Direct Factor Xa Inhibitor

  摘要：

  Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-molecule inhibitors with good oral bioavailability. We identified oxazolidinone derivatives as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.

  DOI：

  10.1021/jm050101d
• 作为产物：
  描述：

  4-(4-吗啉基)苯胺 在 正丁基锂 、 异戊醇 、 N,N-二甲基苯胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.17h， 生成 利奈唑胺杂质22
  参考文献：
  名称：

  Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939):  An Oral, Direct Factor Xa Inhibitor

  摘要：

  Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-molecule inhibitors with good oral bioavailability. We identified oxazolidinone derivatives as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.

  DOI：

  10.1021/jm050101d

文献信息

• An exploratory and mechanistic study of the defluorination of an (aminofluorophenyl)oxazolidinone: SN1(Ar*) vs. SR+N1(Ar*) mechanism
  作者：Elisa Fasani、Fedele Tilocca、Stefano Protti、Daniele Merli、Angelo Albini

  DOI：10.1039/b812372a

  日期：——

  nucleophile such as pyrrole. The rationalization is supported by the study of some related molecules. Thus, the only photochemical reaction from the non fluorinated analogue of linezolid (that ionizes just as 1) is an inefficient degradation of the morpholine chain (Phi 0.001), while a simple model such as N-(2-fluorophenyl)morpholine undergoes photosolvolysis in water and is not trapped by pyrrole.

  在某些产品中，吗啉代氟苯基恶唑烷酮1（抗菌药物利奈唑胺）在水中照射后会发生还原性脱氟（Phi 0.33），其中一些产品会同时发生吗啉侧链的氧化降解。在氯化物，碘化物和吡咯的存在下，氟被这些基团取代（在位置2处有吡咯）。脱氟在甲醇中效率较低，主要导致还原（Phi 0.053）。可以通过两种不同的机制来容纳这些数据。CF键杂合以产生苯基阳离子[S（N）1（Ar *）]，或电离以产生自由基阳离子[S（R（+）N）1（Ar *）]。已收集稳态和时间解析数据来澄清此问题。发现实际上1的电离是有效的，并且是从单重态开始的，但不会导致不可逆转的变化。相反，三重态（3）1（在甲醇中的寿命为0.5微米，在水中为<0.1微米）会碎裂，并给出相应的三重态苯基阳离子。最后一个中间体很好地解释了所观察到的氢在分子间（从溶剂中还原时）和分子内（从吗啉基团）以及从带电阴离子或中性π亲核试剂（如吡咯）中析氢。合理化得到一
• Heterocyclylaminomethyloxazo-lidinones as antibacterials
  申请人：AstraZeneca AB

  公开号：US20030207899A1

  公开（公告）日：2003-11-06

  Compounds of formula (I) 1 , or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q3 and Q5; R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  化合物的公式（I）1，或其药用盐，或其体内可水解酯，其中，例如，HET是一个含有2到4个异原子（N、O和S）的可选择取代的C-连接的5元杂环芳烃环；Q可以从Q3和Q5中选择；R2和R3独立地为氢或氟；T可以从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂环芳烃环系统或一个公式（TC5）的基团：其中Rc是，例如，R13CO—，R13SO2—或R13CS—；其中R13是，例如，可选择取代的（1-10C）烷基或R14C(O)O(1-6C)烷基，其中R14是可选择取代的（1-10C）烷基；作为抗菌剂是有用的；并描述了它们的制备方法和含有它们的药物组合物。
• [EN] METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE PHÉNYLE-5-HYDROXYMÉTHYL-2-OXAZOLIDINONE N-SUBSTITUÉ<br/>[ZH] 一种N-取代苯基-5-羟甲基-2-噁唑烷酮的合成方法
  申请人：HANGZHOU DIKE TECH CO LTD

  公开号：WO2021031533A1

  公开（公告）日：2021-02-25

  本发明公开了一种N-取代苯基-5-羟甲基-2-噁唑烷酮的合成方法，其特征在于，所述合成方法为：以3-R 2-4-R 1-苯胺和环氧氯丙烷为原料进行反应，反应得到的产物在碱性条件和CO 2氛围下制备N-取代苯基-5-羟甲基-2-噁唑烷酮，其中，R 1为吗啉基团、吗啉-3-酮基团或哌嗪及其衍生物基团，R 2为卤素、氢或低碳烷基。本发明提供的合成方法具有步骤少、操作简单、原料价廉易得、反应条件温和、产物收率高等优点，尤其适合抗生素利奈唑胺中间体和抗血栓药物利伐沙班中间体的工业化生产。
• Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
  申请人：Braude Viviana

  公开号：US20070197529A1

  公开（公告）日：2007-08-23

  The present invention provides an isolated linezolid impurity, desfluoro linezolid, the preparation thereof and its use as a reference standard.

  本发明提供了一种孤立的利奈唑胺杂质，去氟利奈唑胺，其制备方法及其用作参考标准。
• Heterocyclylaminomethyloxazolidinones as antibacterials
  申请人：AstraZeneca AB

  公开号：US06734200B1

  公开（公告）日：2004-05-11

  Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，其中，例如，HET是一种可选择的取代的C-连接的5成员杂环芳基环，其中含有2至4个独立选择自N、O和S的杂原子；Q从Q1和Q2中选择，例如：R2和R3独立地为氢或氟；T从一系列基团中选择，例如，一种N-连接的（完全不饱和的）5成员杂环芳基环系统或公式（TC5）的基团：其中Rc是，例如，R13CO—、R13SO2—或R13CS—；其中R13是，例如，可选择的取代的（1-10C）烷基或R14C（O）O（1-6C）烷基，其中R14是可选择的取代的（1-10C）烷基；这些化合物对抗菌有用；并描述了制造它们的过程和含有它们的药物组合物。